Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
See Latest ArticlesAre Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?
Journal of the American Board of Family Medicine, 11/09/09
Ong HT – This objective review shows that the rennin–angiotensin antagonists do not have special cardiovascular protective properties.
Related Articles
Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers for Ischemic Heart Disease
Annals of Internal Medicine, 10/20/09
Relevance Score: 99%
Adenine/cytosine1166 polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors
Journal of Hypertension, 10/26/09
Relevance Score: 98%
Angiotensin-converting enzyme and angiotensin II receptor subtype 2 genotypes in type 1 diabetes and severe hypoglycaemia requiring emergency treatment: a case cohort study
Pharmacogenetics and genomics, 10/26/09
Relevance Score: 97%
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
Vascular Health and Risk Management, 11/13/09
Relevance Score: 96%
Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism: A Prospective Cohort Study in Primary Care
Clinical Drug Investigation, 11/12/09
Relevance Score: 96%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial
Gastroenterology, 12/08/09
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
Gastroenterology, 12/08/09
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor